Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Tuesday 23 November, 2004

XTL Biopharm Ltd


XTL Biopharmaceuticals Ltd
23 November 2004

Cubist Pharmaceuticals and XTL Biopharmaceuticals Announce Completion of
Independent Data and Safety Monitoring Board (DSMB) Review of Phase 2 Data for

DSMB Recommends Continuation of Trial

Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) and XTL Biopharmaceuticals Ltd.
(LSE:XTL) today announced the completion of the first scheduled review by an
independent data and safety monitoring board (DSMB) of the first group of 15
patients enrolled in the ongoing Phase 2 clinical trial. The trial is the second
of two planned Phase 2 trials. This study is examining the safety and efficacy
of HepeX-B (libivirumab and exbivirumab for injection) for prevention of
hepatitis B reinfection in patients who have received liver transplantation for
end-stage hepatitis B infection, and who have been maintained on hepatitis B
immune globulin (HBIg).

The clinical protocol for an open-label study of HepeX-B was designed with input
from the U.S. Food & Drug Administration (FDA) and specifies for periodic
scheduled open-label reviews of the clinical data by an independent DSMB. Based
upon a review of the data provided by XTL, the DSMB, convened by Duke Clinical
Research Institute at Duke University, has recommended continuation of the
trial. Patients are currently being enrolled in the trial in the U.S. and in
Israel. Centres in several Western European countries will be opened shortly.


Dr. Martin Becker, President and CEO           Tel: +1 617 621 1570

Financial Dynamics
Julia Phillips, James Strong                   Tel: +44 (0) 20 7831 3113

Notes to Editor

About XTLbio
XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. XTLbio's HepeXTM product line - now in clinical trials
- has the potential to introduce revolutionary therapies for viral hepatitis,
including prevention of re-infection in transplanted livers, the Company's
primary focus, and a longer-term cocktail approach in treating chronic illness.
XTLbio believes its primary competitive advantage lies in its patented TrimeraTM
technology, which enables the development of fully human monoclonal antibodies
and models of human disease for pre-clinical drug validation. Established in
1993, XTLbio became a public company in 2000 and its shares are listed on the
Official List of the UK Listing Authority and are traded on the London Stock
Exchange under the symbol XTL.

About HBV

Hepatitis B is most commonly caused by the Hepatitis B virus, which, according
to Datamonitor, has infected over 2 billion people around the world. Although a
vaccine against HBV was introduced in 1982, globally, 350 million people are
infected chronically with the disease and approximately 1 million people die
each year as a result of complications from HBV infection. Current treatment
regimens for chronic HBV often include use of interferon alpha or an antiviral
drug. Despite these treatment options, chronic HBV can lead to severe liver
damage and patients may require liver transplantation To prevent re-infection of
the new liver with HBV, patients are currently treated with hepatitis B immune
globulin (HBIg) combined with an antiviral compound, such as lamivudine. The
global market for HBIg is estimated to be about $100 million annually.

About HepeX-B

HepeX-BTM is a combination of two fully human monoclonal antibodies, selected
using XTLbio's pre-clinical TrimeraTM model, that target HBV surface antigens.
It is currently in an international Phase 2 study for the prevention of
infection by HBV in liver transplant patients who have been maintained on HBIg.
In clinical studies, HepeX-BTM maintained serum levels similar to or higher than
the current first-line treatment, HBIg, using 1,000 times less drug. HepeX-BTM
has already been granted Orphan Drug Status in both the U.S. and the European

HepeXTM, TrimeraTM, XTLTM and XTLbioTM are trademarks of XTL Biopharmaceuticals

                      This information is provided by RNS
            The company news service from the London Stock Exchange